Literature DB >> 9188900

Economic consequences of multiple sclerosis for Canadians.

C V Asche1, E Ho, B Chan, P C Coyte.   

Abstract

OBJECTIVES: To estimate the total costs of multiple sclerosis (MS) for all Canadians in 1994.
METHODS: Prevalence-based study estimating disease-related societal costs for Canadians with MS in 1994. The human capital approach was used to estimate the value of lost productivity due to illness. Two components were revealed: first, direct costs, in terms of expenditures on hospital care, other institutions, physician services, other health professionals, drugs, and other expenditures; and second, indirect costs, in terms of lost productivity due to premature mortality and disability.
RESULTS: The total costs of MS for Canadians were $502.3 million in 1994, with direct and indirect cost components at $188.6 million and $313.7 million, respectively.
CONCLUSIONS: This study highlights the scope and magnitude of the economic consequences of MS for Canadians. The costs calculated may be used to provide guidance in the setting of national priorities for research and prevention activities.

Entities:  

Mesh:

Year:  1997        PMID: 9188900     DOI: 10.1111/j.1600-0404.1997.tb00208.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  14 in total

1.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 2.  The economics of multiple sclerosis. Distribution of costs and relationship to disease severity.

Authors:  A N Grudzinski; Z Hakim; E R Cox; J L Bootman
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

Review 3.  Pharmacoeconomic considerations in the treatment of multiple sclerosis.

Authors:  Jessica Sharac; Paul McCrone; Ramon Sabes-Figuera
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

Review 4.  Economic burden of multiple sclerosis: a systematic review of the literature.

Authors:  Huseyin Naci; Rachael Fleurence; Julie Birt; Amy Duhig
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  The direct cost of patients with multiple sclerosis: a survey from Italian MS centres.

Authors:  Berto P; Amato M P; Bellantonio P; Bortolon F; Cavalla P; Florio C; Lugaresi A; Montanari E; Rottoli M; Simone I L; Zaffaroni M
Journal:  Neurol Sci       Date:  2011-04-20       Impact factor: 3.307

Review 6.  Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.

Authors:  M Kendrick; K I Johnson
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

Review 7.  Does pain in individuals with multiple sclerosis affect employment? A systematic review and meta-analysis.

Authors:  Shahnaz Shahrbanian; Mohammad Auais; Pierre Duquette; Katie Andersen; Katie Anderson; Nancy E Mayo
Journal:  Pain Res Manag       Date:  2013 Sep-Oct       Impact factor: 3.037

8.  Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

Authors:  Uwe K Zettl; Thomas Henze; Ute Essner; Peter Flachenecker
Journal:  Eur J Health Econ       Date:  2013-12-01

Review 9.  The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.

Authors:  Ceri J Phillips
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents.

Authors:  Pierluigi Russo; Alessandro Capone; Andrea Paolillo; Francesco Macchia; Federica Ranzato; Gianfranco Costantino; Luca Degli sposti; Luciano Caprino
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.